Abstract
Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are proposed for diagnosis, differential diagnosis, staging, prognostic factors, treatment and response criteria. The guidelines proposed here are intended to contribute to the standardization of the diagnosis and treatment of these patients, and should facilitate the future development of clinical trials that could define more precisely predictive markers for histological progression or lack of response, and evaluate new drugs or treatments.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 487-495 |
| Number of pages | 9 |
| Journal | Leukemia |
| Volume | 22 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2008 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Cancer Research
Cite this
Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. / Matutes, E.; Oscier, D.; Montalban, C.; Berger, F.; Callet-Bauchu, E.; Dogan, A.; Felman, P.; Franco, V.; Iannitto, E.; Mollejo, M.; Papadaki, T.; McPhail, Ellen; Salar, A.; Solé, F.; Stamatopoulos, K.; Thieblemont, C.; Traverse-Glehen, A.; Wotherspoon, A.; Coiffier, B.; Piris, M. A.
In: Leukemia, Vol. 22, No. 3, 03.2008, p. 487-495.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria
AU - Matutes, E.
AU - Oscier, D.
AU - Montalban, C.
AU - Berger, F.
AU - Callet-Bauchu, E.
AU - Dogan, A.
AU - Felman, P.
AU - Franco, V.
AU - Iannitto, E.
AU - Mollejo, M.
AU - Papadaki, T.
AU - McPhail, Ellen
AU - Salar, A.
AU - Solé, F.
AU - Stamatopoulos, K.
AU - Thieblemont, C.
AU - Traverse-Glehen, A.
AU - Wotherspoon, A.
AU - Coiffier, B.
AU - Piris, M. A.
PY - 2008/3
Y1 - 2008/3
N2 - Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are proposed for diagnosis, differential diagnosis, staging, prognostic factors, treatment and response criteria. The guidelines proposed here are intended to contribute to the standardization of the diagnosis and treatment of these patients, and should facilitate the future development of clinical trials that could define more precisely predictive markers for histological progression or lack of response, and evaluate new drugs or treatments.
AB - Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are proposed for diagnosis, differential diagnosis, staging, prognostic factors, treatment and response criteria. The guidelines proposed here are intended to contribute to the standardization of the diagnosis and treatment of these patients, and should facilitate the future development of clinical trials that could define more precisely predictive markers for histological progression or lack of response, and evaluate new drugs or treatments.
UR - http://www.scopus.com/inward/record.url?scp=40749143143&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40749143143&partnerID=8YFLogxK
U2 - 10.1038/sj.leu.2405068
DO - 10.1038/sj.leu.2405068
M3 - Article
C2 - 18094718
AN - SCOPUS:40749143143
VL - 22
SP - 487
EP - 495
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 3
ER -